독일의 COVID-19 팬데믹 완화 제품(COVID-19 의약품 시장, COVID-19 백신 시장, 개인보호구(PPE), Self-collection용 스왑, COVID-19용 인공지능(AI), 원격 방사선 진단, 안구 보호구 등) 시장(-2024년)
Germany COVID-19 Pandemic Mitigation Products (COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, and More) Market to 2024
상품코드 : 955011
리서치사 : Homeland Security Research Corporation (HSRC)
발행일 : 2020년 08월
페이지 정보 : 영문 420 Pages; 220 Tables & Figures
US $ 4,950 ₩ 6,322,000
PDF (Single User License)
US $ 5,950 ₩ 7,599,000
PDF (Departmental License)
US $ 8,950 ₩ 11,430,000
PDF (Site License)
US $ 12,000 ₩ 15,326,000
PDF (Corporate License)


한글목차

독일의 코로나19(COVID-19) 팬데믹 완화 제품 시장 규모는 2020-2024년 누계 640-840억 달러에 이를 전망입니다(연도 및 예측 시나리오에 근거).

독일에서는 연방정부와 지방정부의 협력에 의해 조기에 COVID-19 검사/방지 체제를 갖추었고, 독일 전국토에 190개소 이상의 검사 거점을 정비하며 매주 35만건 이상의 검사를 행했습니다. 그 결과, 팬데믹의 첫번째 파동을 억제하고, 또 급여 보전 등의 경제지원 체제도 마련할 수 있었습니다.

독일의 COVID-19 팬데믹 완화 제품 시장을 분석했으며, 전체 시장 규모(처치 건수) 동향 전망, 주요 제품/서비스별·최종사용자별 상세 동향, 시나리오별 예측, 업계 관계자가 향후 해결해야 할 과제 등의 정보를 정리하여 전해드립니다.

본 보고서의 예측 시나리오

A. 본 보고서의 분석 내용

B. 주요 제품 및 서비스별 분석(총 29개 항목)

최종사용자 시장별 분석(총 6개 항목)

수익원별 분석(총 4개)

C. 시장 부문별 분석 : 분석 프레임워크 상세

D. 주요 기업의 최신 동향과 시장 데이터(총 37개사)

E. COVID-19 팬데믹 완화 커뮤니티 정보원(총 2,300개 이상)

F. 본문에서 언급된 벤더(총 450개사 이상)

G. 부록

LSH 20.11.06
영문 목차

영문목차

Title:
Germany COVID-19 Pandemic Mitigation Products
(COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, CT, X-Ray, Ultrasound, COVID-19 IT, Telemedicine, PACS, Face Shields, PPE Gowns, Coronavirus Homecare, Mechanical Ventilators, Gloves, E-Health, Robotic PCR Market, Point of Care Antigen Test, PCR Reagents, Face Masks, ICU, Contact Tracing, Sterilization Systems, Point of Care Serologic Test, Polymerase Chain Reaction, Test Kits, Surge Hospitals and More) Market to 2024.

On the backdrop of the need for essential medical products and services, a new market has emerged, the COVID-19 pandemic mitigation products market. This Germany COVID-19 pandemic mitigation cumulative 2020-2024 market is worth $64-84 Billion* .

(*) Market size is year and scenario dependent.

To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:

Why trust this report?

Bottom Line: While other COVID-19 reports are written (at best) by MBAs, this report is published by professionals for experts

According to the report:

Angela Merkel, the Chancellor, and a scientist (PhD in Quantum Chemistry) is considered by the majority of the Germans to be the ideal leader for the COVID-19 crisis.

If one big democratic country can be considered to have a "decent" COVID-19 disaster management, it is Germany. Fatalities are fewer than in other countries, the government supports suffering firms, politicians & workers are competent.

Germany used its nationwide network of more than 190 testing laboratories that ramped up its testing capability, before the federal government knew a pandemic was around the corner. Germany conducted 350,000 tests a week and can do many more tests.

As the federal government hesitated, local governments reacted promptly to close down public places and trace COVID-19 infected contacts. Germany was fortunate, as it got an "early warning" from Italy. Germany used the lead time to knock down the pandemic curve.

German enacted prevention protocols in place facilitated the country's response to the outbreak. These protocols included early establishment of testing capacities, high levels of testing and an efficient suppression strategy amongst elder population and cost-effective use of Germany's abundant 660,000 hospital beds.

Exploiting its early accomplishment in segregating the infected, Germany moved to the second phase of the coronavirus pandemic mitigation, tracking each chain of the virus. It established a capacity of more than 4 million tests a week and contact tracing by thousands of "containment scouts" at Germany's public-health organizations.

To protect workers' income, Germany has ramped up Kurzarbeitergeld (Salary for temporary work), an instituted system under which the government covers up to 86% of the missed earnings of workers. While the German vehicle industry ceased production for a while, other industry segments like pharma and petrochemicals kept working.

The IMF forecasts a 7% contraction by 2020, graver than the 2008-2009 crisis. Germany's accomplishments in coping with the coronavirus are indisputable.

Germany's COVID-19 pandemic mitigation products market is driven by the demand for the following:

and the following factors:

This 420 -page market report is the most comprehensive review of the German COVID-19 market available today. The objective of this report is to provide today's strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.

The ‘Germany COVID-19 Pandemic Mitigation Products Market - 2020-2024 ’ report presents a thorough market analysis of 29 products & services, 6 end user, 4 revenue source markets. Furthermore, the report provides updated extensive data of 37 key vendors.

Why Buy this Germany COVID-19 Pandemic Mitigation Products Market Report?

A. Questions answered in this report include:

B. German COVID-19 market size data is analyzed via 5 independent key perspectives. With a highly fragmented market we address the "money trail" - each dollar spent in the German COVID-19 market is analyzed and crosschecked via 3 orthogonal viewpoints:

By 29 Products and Services:

By 6 End User Markets:

By 4 Revenue Source Markets:

C. Detailed market analysis frameworks for each of the market sectors are provided, including:

D. The report provides an updated extensive data of the leading 37 companies

(including companies' profile, recent annual revenues, COVID-19 mitigation activities & products and contact information).

E. The report includes over 2300 links to the COVID-19 pandemic mitigation community information sources

F. The report mentions > 450 Vendors including the following:

Moderna, IBM, 3M Company, Philips NV, Johnson & Johnson, Roche, Nvidia Corporation, Thermo Fisher Scientific, Siemens, Toshiba, Google, Samsung Electronics Co, GE Healthcare, Medtronic, MedWhat, MedyMatch, Merck, Metabiota, Micron Technology, Infermedica, Infervision, Inovio Pharmaceuticals, Microsoft Corporation, Mindshare Medical, Morpheo, Pfizer, Philips NV, Maxim Biotech, Honeywell Safety Products, Philips Healthcare, Siemens, Recursion Pharmaceuticals, Fujifilm Holdings Corporation, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics, Amazon , analyticsMD, Apixio, Apple, Arterys Inc., Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Gateway Safety Inc., General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Imagen Technologies, Imagia Cybernetics, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Oncora Medical, Ovuline, PeerWell, PhysIQ, Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure.Ai, Radians Inc., Roam Analytics, RxPREDICT, Safety Optical Service Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Sigma-Aldrich Corp., Skymind Inc., Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc. and more.

G. Germany COVID-19 market report includes 5 appendices:

COVID-19 pandemic mitigation market research team

The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen identification, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, ultrasound, electron microscopy, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.

As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기